Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 1, 2026, reports the completion of a transaction involving ViiV Healthcare Limited, a global specialist HIV company. The filing details the exit of Pfizer Inc. from its investment in ViiV and the corresponding increase in Shionogi & Co., Ltd.'s stake.
Key Financial Metrics and Transaction Details
- Shareholding Changes: Shionogi increased its economic interest in ViiV Healthcare to 21.7%. GSK maintains a 78.3% majority economic interest. Pfizer's 11.7% economic interest was fully exited.
- Transaction Consideration: ViiV Healthcare issued new shares to Shionogi for a total consideration of $2.125 billion.
- Proceeds Distribution: Pfizer received $1.875 billion. GSK received a special dividend of $0.250 billion (paid in GBP).
- Accounting Impact: The Pfizer put option liability recorded in GSK's accounts for the year ended December 31, 2025, was extinguished through retained earnings upon completion.
- Financial Performance: The filing text does not provide clear values for overall revenue, profit, cash flow, margins, debt, or liquidity for GSK plc.
Material Changes Versus Prior Period
The primary material change is the restructuring of ViiV Healthcare's ownership. The fair value change in the Pfizer put option liability, remeasured immediately prior to completion, was recognized as an adjusting item through other operating income. This contrasts with the prior period where the liability was outstanding on the balance sheet.
Guidance, Outlook, and Risks
The announcement contains forward-looking statements regarding the transaction and future expectations. GSK and Shionogi explicitly disclaim any obligation to update these statements. The filing references risks and uncertainties that could cause actual results to differ materially, directing investors to the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025 for a comprehensive list of contingencies.
Key Facts for Investor Verification
- Confirm the exact GBP equivalent of the $0.250 billion special dividend received by GSK.
- Verify the specific impact of the "adjusting item" on other operating income in the next quarterly report.
- Review the updated capital structure of ViiV Healthcare following the issuance of new shares to Shionogi.
- Check the Form 20-F for 2025 to understand the baseline risk factors referenced in this filing.